In Vivo Mucosal Delivery of Bioactive Human Interleukin 1 Receptor Antagonist Produced by Streptococcus Gordonii

Overview

Journal BMC Biotechnol

Publisher Biomed Central

Specialty Biotechnology

Date 2003 Sep 18

PMID 13129437

Citations 13

Authors

Susanna Ricci

Giovanni Macchia

Paolo Ruggiero

Tiziana Maggi

Paola Bossu

Li Xu

Donata Medaglini

Aldo Tagliabue

Lennart Hammarstrom

Gianni Pozzi

Diana Boraschi

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin-1 (IL-1) is a cytokine involved in the initiation and amplification of the defence response in infectious and inflammatory diseases. IL-1 receptor antagonist (IL-1ra) is an inactive member of the IL-1 family and represents one of the most potent mechanisms for controlling IL-1-dependent inflammation. IL-1ra has proven effective in the therapy of acute and chronic inflammatory diseases in experimental animal models and also in preliminary clinical trials. However, optimisation of therapeutic schedules is still needed. For instance, the use of drug delivery systems targeting specific mucosal sites may be useful to improve topical bioavailability and avoid side effects associated with systemic administration.

Results: In order to develop systems for the delivery of IL-1ra to mucosal target sites, a Streptococcus gordonii strain secreting human IL-1ra was constructed. The recombinant IL-1ra produced by S. gordonii was composed of the four amino acid residues RVFP of the fusion partner at the N-terminus, followed by the mature human IL-1ra protein. RFVP/IL-1ra displayed full biological activity in vitro in assays of inhibition of IL-1beta-induced lymphocyte proliferation and was released by recombinant S. gordonii in vivo both at the vaginal and the gastrointestinal mucosa of mice. RFVP/IL-1ra appeared beneficial in the model of ulcerative colitis represented by IL-2-/- mice (knock-out for the interleukin-2 gene), as shown by the body weight increase of IL-2-/- mice locally treated with S. gordonii producing RFVP/IL-1ra.

Conclusions: These results indicate that recombinant S. gordonii can be successfully used as a delivery system for the selective targeting of mucosal surfaces with therapeutic proteins.

Citing Articles

Research and application of intelligent diagnosis and treatment engineering bacteria.

Zhao N, Chen J, Shi J, Gao Y, Li L, Dong L Front Bioeng Biotechnol. 2025; 12:1524376.

PMID: 39744595 PMC: 11688493. DOI: 10.3389/fbioe.2024.1524376.

IL-1 receptor antagonist: etiological and drug delivery systems overview.

Ubhe A Inflamm Res. 2024; 73(12):2231-2247.

PMID: 39455436 DOI: 10.1007/s00011-024-01960-y.

Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives.

Abouelela M, Helmy Y Microorganisms. 2024; 12(3).

PMID: 38543481 PMC: 10972033. DOI: 10.3390/microorganisms12030430.

Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome.

Lee Y, Kamada N, Moon J Adv Drug Deliv Rev. 2021; 179():114021.

PMID: 34710529 PMC: 8665886. DOI: 10.1016/j.addr.2021.114021.

Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.

Yang C, Merlin D Int J Nanomedicine. 2020; 14:8875-8889.

PMID: 32009785 PMC: 6859086. DOI: 10.2147/IJN.S210315.

References

TAKII T, Honda H, Sasayama S, Kobayashi T, Ikezawa H, Udaka S . Human interleukin-1 receptor antagonist: large-scale expression in Bacillus brevis 47-5Q. J Interferon Cytokine Res. 1999; 19(11):1325-31. DOI: 10.1089/107999099313000. View

Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G . The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS. 2002; 16(10):1351-6. DOI: 10.1097/00002030-200207050-00006. View

Ricci S, Medaglini D, Rush C, Marcello A, Peppoloni S, Manganelli R . Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii. Infect Immun. 2000; 68(2):760-6. PMC: 97203. DOI: 10.1128/IAI.68.2.760-766.2000. View

Dinarello C . Proinflammatory cytokines. Chest. 2000; 118(2):503-8. DOI: 10.1378/chest.118.2.503. View

Steidler L, Hans W, SCHOTTE L, Neirynck S, Obermeier F, Falk W . Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000; 289(5483):1352-5. DOI: 10.1126/science.289.5483.1352. View

de Villiers W, Varilek G, de Beer F, Guo J, Kindy M . Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. Cytokine. 2000; 12(9):1337-47. DOI: 10.1006/cyto.2000.0716. View

Beninati C, Oggioni M, Boccanera M, Spinosa M, Maggi T, Conti S . Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol. 2000; 18(10):1060-4. DOI: 10.1038/80250. View

Hedley M . Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev. 2000; 44(2-3):195-207. DOI: 10.1016/s0169-409x(00)00095-8. View

Shanahan F . Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001; 120(3):622-35. DOI: 10.1053/gast.2001.22122. View

10.

Krishnan B . Interleukin-1 receptor antagonist gene therapy for arthritis. Curr Opin Mol Ther. 2001; 1(4):454-7. View

11.

Holtmann M, Galle P, Neurath M . Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther. 2001; 1(3):455-66. DOI: 10.1517/14712598.1.3.455. View

12.

Bermudez-Humaran L, Langella P, Cortes-Perez N, Gruss A, Tamez-Guerra R, Oliveira S . Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun. 2003; 71(4):1887-96. PMC: 152106. DOI: 10.1128/IAI.71.4.1887-1896.2003. View

13.

Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B . Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003; 21(7):785-9. DOI: 10.1038/nbt840. View

14.

Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson R . Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990; 348(6301):550-2. DOI: 10.1038/348550a0. View

15.

Pozzi G, Musmanno R, Lievens P, Oggioni M, Plevani P, Manganelli R . Method and parameters for genetic transformation of Streptococcus sanguis Challis. Res Microbiol. 1990; 141(6):659-70. DOI: 10.1016/0923-2508(90)90060-4. View

16.

Wakabayashi G, Gelfand J, Burke J, Thompson R, Dinarello C . A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991; 5(3):338-43. DOI: 10.1096/fasebj.5.3.1825816. View

17.

Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I . Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 1991; 352(6336):621-4. DOI: 10.1038/352621a0. View

18.

Stoppacciaro A, Bossu P, Ghiara P, Ruco L, Censini S, Scapigliati G . Binding of IL-1 beta to IL-1R type II at single cell level. J Immunol. 1991; 147(5):1561-6. View

19.

Poole S, Gaines Das R . The international standards for interleukin-1 alpha and interleukin-1 beta. Evaluation in an international collaborative study. J Immunol Methods. 1991; 142(1):1-13. DOI: 10.1016/0022-1759(91)90286-o. View

20.

Sadlack B, Merz H, Schorle H, Schimpl A, Feller A, Horak I . Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993; 75(2):253-61. DOI: 10.1016/0092-8674(93)80067-o. View